Next, cell confluence measured by IncuCyte, and Bliss and HAS synergy scores obtained from the combination of different concentrations of Topotecan (from 0.1 to 30 nM), and SGSS05-NS3 or UNC0379 (from 0.1 to 30 μM) in the indicated 5 NB cells, were evaluated as the difference between the attended and the observed cell confluency (Fig. 7B-F and Figures S7D and S7E and Table S3). The gene discussed is KRAS; the disease is neuroblastoma.